Optimi Health announced plans this week for a Phase 2 trial of up to 200 participants testing natural psilocybin for major depressive disorder, authorized to proceed by Health Canada and set to begin in the first half of 2027. On its own, that’s a future-dated announcement with no data behind it yet. What makes it worth attention now is how the company says it’s paying for it: comfortably from current cash on hand. That cash includes the proceeds of a US$15 million public offering completed in May alongside the company’s Nasdaq uplisting, so this is not a business running on product income alone. What sets Optimi apart is that product income exists at all. The scale matters, though. Optimi reported C$239,700 in total revenue for the nine months ended June 30, against a C$5.55 million net loss and C$13.07 million in cash. The commercial channel is real, but it is not yet financing the company at anything close to the scale of its development spending.
A company that’s already getting paid for psilocybin
The clinical-stage peers examined here remain pre-revenue: Compass, developing synthetic psilocybin, Definium, developing LSD, and Reunion, developing luvesilocin, a prodrug of the psilocin analog 4-OH-DiPT, are financing development with raised capital ahead of product income, while Usona, a nonprofit, operates on philanthropic funding. Optimi isn’t in either position. It’s been shipping GMP-manufactured natural psilocybin capsules to Australia since September 2025 under the country’s Authorised Prescriber Scheme, the same individual-physician authorization pathway examined here when New Zealand adopted a similar model for MDMA. Those Australian sales are reimbursed, not just permitted, by a mix of public and private payers: the Department of Veterans’ Affairs, the National Disability Insurance Scheme, WorkCover, and the private insurer Medibank, per the company’s own reporting. Optimi cites more than 750 clinicians trained to deliver the therapy; that figure matches the total graduate count of Mind Medicine Australia’s general psychedelic-assisted therapy training program, which spans Australia, New Zealand, and international clinicians and is not specific to Optimi’s product. That gives Optimi a commercial product channel operating alongside its clinical-development program, even though current revenue remains small relative to the capital supporting the business.
Why natural psilocybin is a separate technical bet
The leading U.S. registrational psilocybin programs, including Compass’s COMP360 and Usona’s program, use synthetic psilocybin, manufactured for batch-to-batch chemical consistency. Optimi’s trial uses naturally derived psilocybin instead, extracted from cultivated mushrooms rather than synthesized from scratch. The company is billing this as among the largest studies of naturally sourced psilocybin to date, a distinct manufacturing and regulatory bet from the synthetic approach the rest of the field has standardized on, with its own separate questions about batch consistency that a synthetic formulation doesn’t have to answer the same way.
How this fits the sector’s different strategies
Several distinct approaches are emerging for how large and small companies pursue this same underlying opportunity: acquiring a late-stage asset outright, building a defensible patent estate from scratch, betting that existing trial data can be reargued instead of replaced. Optimi’s approach is a fourth, distinct path, and it’s a hybrid: establish commercial product sales through existing access pathways while still raising capital for clinical development, instead of waiting for a registrational approval before generating any product revenue. That does not make Optimi independent of capital markets; its trial budget rests on a cash position built partly from May’s equity raise. What it does give the company is something most clinical-stage psychedelic developers do not yet have: a commercial product channel operating alongside its development program.
What isn’t yet known
Optimi says it is not aware of any serious adverse events reported under Australia’s Authorised Prescriber scheme across more than two years of regulated commercial use, a company statement about the scheme as a whole, with no published pharmacovigilance data behind it, and one worth weighing against the fact that Optimi’s own psilocybin capsules have been shipping only since September 2025. The trial itself has no results to evaluate, dosing isn’t expected to complete until the end of 2027, and Health Canada authorization to proceed is not the same as evidence the trial will succeed. And however a trial is paid for, it still needs to clear the same scientific and regulatory bar; commercial structure changes nothing about what the work has to prove.
There is also an unresolved thread in the public record. Optimi and ATMA Journey Centers announced a Health Canada No Objection Letter in August 2024 for a 200-participant Phase 2 study of psilocybin-assisted psychotherapy in frontline healthcare workers with depression related to COVID-19, with dosing once planned for 2025. The new announcement describes a study of similar scale in general major depressive disorder, names no partner, and states Optimi will hold exclusive ownership of the trial results. Public disclosures do not yet establish whether this is a new trial or a restructuring of the previously authorized program.
Why this is worth tracking regardless of how the trial turns out
Most psychedelic drug developers have to raise capital long before they can generate any product revenue. Optimi is unusual because commercial sales arrived before registrational development was complete. Those sales do not eliminate its dependence on financing, and nothing yet shows product revenue funding registrational work on its own. The question worth tracking, whether or not this specific trial succeeds, is whether an international commercial access channel can become meaningful enough over time to reduce, supplement, or reshape the capital a psychedelic drug program requires. Optimi gives the sector a useful test case for that question.